Article
The Diagnostic Utility of the Point-of-Care CYP2C19 Genotyping Assay in Patients with Acute Coronary Syndrome Dosing Clopidogrel: Comparison with Platelet Function Test and SNP Genotyping.
Annals of clinical and laboratory science - 1 Sept 2016
Choi Jae-Lim, Kim Bo-Ram, Woo Kwang-Sook, Kim Kyeong-Hee, Kim Jeong-Man, Kim Moo-Hyun, Han Jin-Yeong
Abstract excerpt
BACKGROUND: Clopidogrel is a widely used antiplatelet agent for dual antiplatelet therapy and metabolized by CYP2C19. The polymorphism of CYP2C19 is associated with the therapeutic effect of clopidogrel. METHODS: A total of 119 patients diagnosed with acute coronary syndrome (ACS) and underwent percutaneous coronary intervention (PCI) with drug-eluting stents was enrolled. Polymorphisms of CYP2C19 *2,*3,*17 were...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
